{"nctId":"NCT03809429","briefTitle":"Follitropin Delta in Long GnRH Agonist and GnRH Antagonist Protocols (BEYOND)","startDateStruct":{"date":"2019-04-29","type":"ACTUAL"},"conditions":["Infertility, Female"],"count":437,"armGroups":[{"label":"FE 999049 + GnRH agonist (GONAPEPTYL)","type":"EXPERIMENTAL","interventionNames":["Drug: FE 999049 + GnRH agonist (GONAPEPTYL)"]},{"label":"FE 999049 + GnRH antagonist (CETROTIDE)","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: FE 999049 + GnRH antagonist (CETROTIDE)"]}],"interventions":[{"name":"FE 999049 + GnRH agonist (GONAPEPTYL)","otherNames":[]},{"name":"FE 999049 + GnRH antagonist (CETROTIDE)","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Infertile women aged 18-40 undergoing their first IVF/ICSI cycle that are in good physical and mental health and that have been diagnosed with problems in the fallopian tubes, mild endometriosis or have partners with decreased sperm quality.\n* The participants must have a regular menstrual cycle, a normal uterus and 2 normal ovaries.\n* The allowed body mass index is 17.5-32 Kg/m\\^2.\n\nExclusion Criteria:\n\n* Women with very high ovarian reserve, strong preference for either treatment, severe endometriosis, history of repeated miscarriage, couples with known problems in the chromosomes, history or high risk of producing blood cloths, women known to have chronic diseases, women recently participating in trials with non-registered drugs.","healthyVolunteers":false,"sex":"FEMALE","genderBased":true,"genderDescription":"Women undergoing their first IVF/ICSI cycle and aged 18-40 years will be included.","minimumAge":"18 Years","maximumAge":"40 Years","stdAges":["ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Oocytes Retrieved","description":"The number of oocytes retrieved was recorded at the oocyte retrieval visit.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.1","spread":"5.9"},{"groupId":"OG001","value":"9.6","spread":"5.5"}]}]}]},{"type":"SECONDARY","title":"Proportion of Subjects With Cycle Cancellation Due to Poor Ovarian Response or Excessive Ovarian Response","description":"For each participant, the reason for cycle cancellation was recorded","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Proportion of Subjects With Blastocyst Transfer Cancellation After Oocyte Retrieval Due to (Risk of) Ovarian Hyperstimulation Syndrome (OHSS)","description":"For each participant, the reason for blastocyst transfer cancellation was recorded.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"27","spread":null},{"groupId":"OG001","value":"30","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13","spread":null},{"groupId":"OG001","value":"18","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Follicles","description":"The total number of follicles and the number of follicles per size category will be reported","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15.2","spread":"6.3"},{"groupId":"OG001","value":"14.9","spread":"6.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.6","spread":"4.3"},{"groupId":"OG001","value":"7.1","spread":"3.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.6","spread":"2.7"},{"groupId":"OG001","value":"3.8","spread":"2.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18.3","spread":"7.1"},{"groupId":"OG001","value":"17.1","spread":"8.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14.8","spread":"6.4"},{"groupId":"OG001","value":"13.3","spread":"6.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12.2","spread":"5.3"},{"groupId":"OG001","value":"10.9","spread":"5.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.9","spread":"3.7"},{"groupId":"OG001","value":"7.2","spread":"3.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.8","spread":"2.1"},{"groupId":"OG001","value":"4.6","spread":"2.0"}]}]}]},{"type":"SECONDARY","title":"Proportion of Subjects With <4, 4-7, 8-14, 15-19 and â‰¥20 Oocytes Retrieved","description":"Grouped according to number of oocytes","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13","spread":null},{"groupId":"OG001","value":"26","spread":null}]},{"measurements":[{"groupId":"OG000","value":"47","spread":null},{"groupId":"OG001","value":"56","spread":null}]},{"measurements":[{"groupId":"OG000","value":"84","spread":null},{"groupId":"OG001","value":"82","spread":null}]},{"measurements":[{"groupId":"OG000","value":"42","spread":null},{"groupId":"OG001","value":"29","spread":null}]},{"measurements":[{"groupId":"OG000","value":"16","spread":null},{"groupId":"OG001","value":"11","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Metaphase II Oocytes","description":"Only applicable for those inseminated using ICSI","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.2","spread":"4.8"},{"groupId":"OG001","value":"7.9","spread":"4.7"}]}]}]},{"type":"SECONDARY","title":"Fertilization Rate","description":"Measured by the number of pronuclei. Fertilized oocytes with 2 pronuclei were regarded as correctly fertilized","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"53.8","spread":"24.1"},{"groupId":"OG001","value":"54.4","spread":"26.8"}]}]}]},{"type":"SECONDARY","title":"Number of Embryos","description":"The number of embryos (total and good-quality) was reported. Embryo quality is determined by combined assessment of cleavage stage (number of blastomeres/compaction status) and embryo morphology parameters","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.7","spread":"3.9"},{"groupId":"OG001","value":"5.0","spread":"3.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.0","spread":"3.2"},{"groupId":"OG001","value":"3.9","spread":"3.3"}]}]}]},{"type":"SECONDARY","title":"Number of Blastocysts","description":"The number of blastocysts (total and good-quality) was reported. Blastocyst quality is assessed by blastocyst expansion and hatching status, blastocyst inner cell mass grading, and trophectoderm grading. The scoring is based on the classification system by Gardner and Schoolcraft, with additional categories for inner cell mass (degenerative or no inner cell mass) and trophectoderm (degenerative or very large cells)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.8","spread":"3.1"},{"groupId":"OG001","value":"3.3","spread":"2.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.3","spread":"2.3"},{"groupId":"OG001","value":"2.1","spread":"2.2"}]}]}]},{"type":"SECONDARY","title":"Circulating Concentrations of Follicle-stimulating Hormone (FSH)","description":"Blood samples for analysis of circulating concentrations of FSH were drawn.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15.5","spread":"4.3"},{"groupId":"OG001","value":"16.7","spread":"4.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.2","spread":"4.4"},{"groupId":"OG001","value":"15.8","spread":"4.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.4","spread":"2.8"},{"groupId":"OG001","value":"9.8","spread":"2.9"}]}]}]},{"type":"SECONDARY","title":"Circulating Concentrations of Luteinizing Hormone (LH)","description":"Blood samples for analysis of circulating concentrations of LH were drawn","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.5","spread":"0.9"},{"groupId":"OG001","value":"5.6","spread":"6.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.8","spread":"0.9"},{"groupId":"OG001","value":"1.8","spread":"1.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.2","spread":"0.2"},{"groupId":"OG001","value":"2.0","spread":"2.1"}]}]}]},{"type":"SECONDARY","title":"Circulating Concentrations of Estradiol","description":"Blood samples for analysis of circulating concentrations of estradiol were drawn","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1190.1","spread":"1101.2"},{"groupId":"OG001","value":"2675.8","spread":"1544.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7542.7","spread":"4106.8"},{"groupId":"OG001","value":"6487.7","spread":"3960.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3485.1","spread":"2129.0"},{"groupId":"OG001","value":"3163.5","spread":"1865.0"}]}]}]},{"type":"SECONDARY","title":"Circulating Concentrations of Progesterone","description":"Blood samples for analysis of circulating concentrations of progesterone were drawn","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.8","spread":"1.0"},{"groupId":"OG001","value":"2.6","spread":"1.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.1","spread":"1.4"},{"groupId":"OG001","value":"3.5","spread":"2.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"25.9","spread":"12.9"},{"groupId":"OG001","value":"26.0","spread":"13.2"}]}]}]},{"type":"SECONDARY","title":"Circulating Concentrations of Inhibin B","description":"Blood samples for analysis of circulating concentrations of Inhibin B were drawn","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"690.4","spread":"419.1"},{"groupId":"OG001","value":"808.2","spread":"428.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1032.6","spread":"605.2"},{"groupId":"OG001","value":"938.1","spread":"570.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"416.6","spread":"253.9"},{"groupId":"OG001","value":"389.0","spread":"226.6"}]}]}]},{"type":"SECONDARY","title":"Total Gonadotropin Dose","description":"Calculated by start dates, end dates and daily dose of investigational medicinal product","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"112.2","spread":"28.9"},{"groupId":"OG001","value":"96.5","spread":"26.0"}]}]}]},{"type":"SECONDARY","title":"Number of Stimulation Days","description":"Calculated by start dates and end dates","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.4","spread":"1.9"},{"groupId":"OG001","value":"8.8","spread":"1.8"}]}]}]},{"type":"SECONDARY","title":"Positive Beta Human Chorionic Gonadotropin (Î²hCG) Rate","description":"Defined as positive serum Î²hCG test","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"91","spread":null},{"groupId":"OG001","value":"79","spread":null}]},{"measurements":[{"groupId":"OG000","value":"111","spread":null},{"groupId":"OG001","value":"125","spread":null}]}]}]},{"type":"SECONDARY","title":"Implantation Rate","description":"Defined as the number of gestational sacs after transfer divided by number of blastocysts transferred","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"82","spread":null},{"groupId":"OG001","value":"68","spread":null}]}]}]},{"type":"SECONDARY","title":"Clinical Pregnancy Rate","description":"Defined as at least one gestational sac","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"81","spread":null},{"groupId":"OG001","value":"68","spread":null}]},{"measurements":[{"groupId":"OG000","value":"121","spread":null},{"groupId":"OG001","value":"136","spread":null}]}]}]},{"type":"SECONDARY","title":"Vital Pregnancy Rate","description":"Defined as at least one intrauterine gestational sac with fetal heart beat","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"77","spread":null},{"groupId":"OG001","value":"62","spread":null}]},{"measurements":[{"groupId":"OG000","value":"125","spread":null},{"groupId":"OG001","value":"142","spread":null}]}]}]},{"type":"SECONDARY","title":"Ongoing Pregnancy Rate","description":"At least one intrauterine viable fetus","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"73","spread":null},{"groupId":"OG001","value":"60","spread":null}]},{"measurements":[{"groupId":"OG000","value":"129","spread":null},{"groupId":"OG001","value":"144","spread":null}]}]}]},{"type":"SECONDARY","title":"Ongoing Implantation Rate","description":"Defined as number of intrauterine viable fetuses divided by the number of blastocysts transferred","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"74","spread":null},{"groupId":"OG001","value":"60","spread":null}]}]}]},{"type":"SECONDARY","title":"Proportion of Subjects With Early OHSS (Including OHSS of Moderate/Severe Grade)","description":"Classification of grade was according to Golan's classification system, and all OHSS cases were graded as mild, moderate or severe.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]}]},{"type":"SECONDARY","title":"Proportion of Subjects With Late OHSS (Including OHSS of Moderate/Severe Grade)","description":"Classification of grade was according to Golan's classification system, and all OHSS cases were graded as mild, moderate or severe.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]}]},{"type":"SECONDARY","title":"Frequency of Adverse Events","description":"Any untoward medical occurrence","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"112","spread":null},{"groupId":"OG001","value":"109","spread":null}]}]}]},{"type":"SECONDARY","title":"Intensity of Adverse Events","description":"Categorized as mild, moderate or severe","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"42.6","spread":null},{"groupId":"OG001","value":"41.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18.8","spread":null},{"groupId":"OG001","value":"16.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.0","spread":null},{"groupId":"OG001","value":"3.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Technical Malfunctions of the Pre-filled Injection Pen","description":"Incidences of technical malfunctions of the pre-filled injection pen were recorded","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":4,"n":202},"commonTop":["Headache","Procedural pain","Pelvic pain","Ovarian hyperstimulation syndrome","Biochemical pregnancy"]}}}